img
Epidemiological Analysis of CCHFv Strains in Turkey and Assessment of the Utility of Non-invasive Samples to Diagnostics
Proje Ekibi
Prof. Dr. Zati VATANSEVER
Kafkas Üniversitesi, Türkiye
Projedeki Rolü: Araştırmacı
Proje Türü (Uluslararası) Diğer Uluslararası Kurum ve Kuruluşlar
Proje No -
Proje Konusu Crimean-Congo Haemorrhagic fever (CCHF) is a fatal disease caused by a virus transmitted to humans by a bite from an infected tick or through direct contact with infected meat. Human-to-human transmission can also occur, resulting in outbreaks which may be difficult to control. CCHF virus (CCHFv) is a growing threat to naïve populations climate change as well as increasing globalization are broadening its worldwide footprint. Turkey is the country in which CCHFv is most endemic with over 1000 cases registered annually. CCHFv is highly diverse: commercial diagnostics rely on data amalgamated from multiple virus strains and countries. In Turkey there is concern that new genetic variations of CCHFv have emerged which are not recognized by currently available diagnostic tests.The goal of this project is to develop risk maps of CCHF, improve local nucleic acid diagnostics, and examine any correlation between virus strains and disease severity. The project will bring together expertise on (i) tick vector mapping and entomology at Kafkas University, (ii) human CCHF disease, at Sivas Cumhuriyet University, and (iii) CCHFv diagnostics and genomics at the WHO-Collaborating Centre on Viral Haemorrhagic Fevers, PHE.PHE will update its published CCHFv diagnostic assay, create a panel of controls to facilitate accurate interpretation, and transition the assay to Turkey. In Turkey, biobanks will be developed for (a) ticks and (b) clinical samples which will be used to compare detection capabilities in serum, dried blood spots, urine and saliva. Viral samples will also be sequenced and used to construct risk maps and to assess correlations between disease and virus strain.The project will improve accuracy speed of diagnosis, improving outcomes for patients and reducing risks to public health in Turkey. Better assays will improve efficiency of clinicians in diagnosing and treating disease. Biotech developments will catalyze economic growth and increase social welfare.
Proje Durumu Tamamlandı
Başlangıç Tarihi 01-01-2020
Bitiş Tarihi 01-04-2023
BM Sürdürülebilir Kalkınma Amaçları

Paylaş